Mumbai: The global pharmaceutical sector witnessed a sharp downturn after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented medicines, effective October 1, 2025. The announcement sent shockwaves across international markets, with Indian pharmaceutical stocks bearing the brunt of investor anxiety.

On the domestic front, the BSE Sensex opened sharply lower, shedding nearly 400 points, while the Nifty index slipped below the critical 24,800 level. The Indian pharmaceutical index itself plunged by 2.3%, marking one of the steepest declines in recent months. Companies such as Sun Pharmaceutical Industries were among the hardest hit, with share prices falling by 3.4%, reflecting heightened investor concerns over export earnings and future trade restriction

See Full Page